Allos Therapeutics, Inc. today announced that it has submitted a request to the European Medicines Agency for a re-examination of the negative opinion issued in January by the EMA’s Committee For Medicinal Products for Human Use for conditional approval of FOLOTYN® for the treatment of patients with peripheral T-cell lymphoma whose disease has progressed after at least one prior systemic therapy.